The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
(S)-3-(4-((5-(spiro[indene-1,4'-piperidine]-1'-ylmethyl)thiophen-2-yl)methoxy)phenyl)hex-4-ynoic acid ID: ALA4782004
Cas Number: 1309435-60-6
PubChem CID: 52936292
Product Number: G650461, Order Now?
Max Phase: Preclinical
Molecular Formula: C31H31NO3S
Molecular Weight: 497.66
Molecule Type: Unknown
Associated Items:
Names and Identifiers Canonical SMILES: CC#C[C@@H](CC(=O)O)c1ccc(OCc2ccc(CN3CCC4(C=Cc5ccccc54)CC3)s2)cc1
Standard InChI: InChI=1S/C31H31NO3S/c1-2-5-25(20-30(33)34)23-8-10-26(11-9-23)35-22-28-13-12-27(36-28)21-32-18-16-31(17-19-32)15-14-24-6-3-4-7-29(24)31/h3-4,6-15,25H,16-22H2,1H3,(H,33,34)/t25-/m0/s1
Standard InChI Key: YSVQUSMRABAJAR-VWLOTQADSA-N
Molfile:
RDKit 2D
36 40 0 0 0 0 0 0 0 0999 V2000
38.9169 -19.3871 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
39.4107 -18.7361 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
40.2215 -18.8382 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
40.7154 -18.1871 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
41.5267 -18.2910 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
42.0204 -17.6408 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
41.7036 -16.8865 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
40.8883 -16.7865 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
40.3982 -17.4378 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
42.1966 -16.2348 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
43.0075 -16.3359 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
41.8786 -15.4820 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
41.5545 -14.7251 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
41.2328 -13.9739 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
43.5005 -15.6842 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
44.3114 -15.7853 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
43.1826 -14.9314 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
35.1994 -19.3681 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
35.1574 -20.1829 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
35.8383 -20.6242 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
36.5654 -20.2555 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
36.6074 -19.4406 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
35.9223 -18.9946 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
33.1128 -19.2709 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
32.8598 -20.0504 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
33.4078 -20.6572 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
34.2090 -20.4857 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
33.9094 -19.0985 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
34.4555 -19.7040 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
35.1143 -18.5608 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
34.3165 -18.3921 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
37.2506 -20.7009 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
37.9789 -20.3303 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
38.7065 -20.6971 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
39.2846 -20.1196 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
38.1068 -19.5188 0.0000 S 0 0 0 0 0 0 0 0 0 0 0 0
1 2 1 0
2 3 1 0
3 4 1 0
4 5 2 0
5 6 1 0
6 7 2 0
7 8 1 0
8 9 2 0
9 4 1 0
7 10 1 0
10 11 1 0
10 12 1 1
12 13 3 0
13 14 1 0
11 15 1 0
15 16 1 0
15 17 2 0
18 19 1 0
18 23 1 0
19 20 1 0
20 21 1 0
21 22 1 0
22 23 1 0
24 25 2 0
25 26 1 0
26 27 2 0
27 29 1 0
28 24 1 0
28 29 2 0
29 18 1 0
18 30 1 0
30 31 2 0
31 28 1 0
21 32 1 0
32 33 1 0
33 34 2 0
34 35 1 0
35 1 2 0
1 36 1 0
36 33 1 0
M END Associated Targets(Human) Associated Targets(non-human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 497.66Molecular Weight (Monoisotopic): 497.2025AlogP: 6.47#Rotatable Bonds: 8Polar Surface Area: 49.77Molecular Species: ZWITTERIONHBA: 4HBD: 1#RO5 Violations: 1HBA (Lipinski): 4HBD (Lipinski): 1#RO5 Violations (Lipinski): 1CX Acidic pKa: 3.70CX Basic pKa: 8.83CX LogP: 3.98CX LogD: 3.97Aromatic Rings: 3Heavy Atoms: 36QED Weighted: 0.36Np Likeness Score: -0.19
References 1. Hamdouchi C,Kahl SD,Patel Lewis A,Cardona GR,Zink RW,Chen K,Eessalu TE,Ficorilli JV,Marcelo MC,Otto KA,Wilbur KL,Lineswala JP,Piper JL,Coffey DS,Sweetana SA,Haas JV,Brooks DA,Pratt EJ,Belin RM,Deeg MA,Ma X,Cannady EA,Johnson JT,Yumibe NP,Chen Q,Maiti P,Montrose-Rafizadeh C,Chen Y,Reifel Miller A. (2016) The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470)., 59 (24.0): [PMID:27749056 ] [10.1021/acs.jmedchem.6b00892 ]